scholarly journals The role of patient, tumour and system factors in socioeconomic inequalities in lung cancer treatment: population-based study

2014 ◽  
Vol 111 (3) ◽  
pp. 608-618 ◽  
Author(s):  
L F Forrest ◽  
M White ◽  
G Rubin ◽  
J Adams
Keyword(s):  
Lung Cancer ◽  
Cancer Treatment ◽  
Population Based ◽  
Socioeconomic Inequalities ◽  
Population Based Study ◽  
Lung Cancer Treatment ◽  
System Factors ◽  
Treatment Population

scholarly journals The Role of Surgery in Lung Cancer Treatment

Cancers ◽  
2020 ◽  
Vol 12 (10) ◽  
pp. 2777
Author(s):  
Francesco Petrella
Keyword(s):  
Lung Cancer ◽  
Cancer Treatment ◽  
Lung Cancer Treatment

 [...]

scholarly journals Lung cancer treatment rates and the role of the lung cancer nurse specialist: a qualitative study

BMJ Open ◽  
2015 ◽  
Vol 5 (12) ◽  
pp. e008587 ◽  
Author(s):  
Angela Mary Tod ◽  
Judy Redman ◽  
Ann McDonnell ◽  
Diana Borthwick ◽  
John White
Keyword(s):  
Lung Cancer ◽  
Qualitative Study ◽  
Cancer Treatment ◽  
Nurse Specialist ◽  
Lung Cancer Treatment

Role of Genotyping in Non-Small Cell Lung Cancer Treatment

Drugs ◽  
2011 ◽  
Vol 71 (17) ◽  
pp. 2231-2246 ◽  
Author(s):  
Laura Bonanno ◽  
Adolfo Favaretto ◽  
Massimo Rugge ◽  
Miquel Taron ◽  
Rafael Rosell
Keyword(s):  
Lung Cancer ◽  
Cancer Treatment ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Treatment

Role of the Glutathione Metabolic Pathway in Lung Cancer Treatment and Prognosis: A Review

2006 ◽  
Vol 24 (11) ◽  
pp. 1761-1769 ◽  
Author(s):  
Ping Yang ◽  
Jon O. Ebbert ◽  
Zhifu Sun ◽  
Richard M. Weinshilboum
Keyword(s):  
Lung Cancer ◽  
Drug Resistance ◽  
Treatment Outcome ◽  
Cancer Treatment ◽  
Metabolic Pathway ◽  
Drug Efficacy ◽  
Glutathione System ◽  
Lung Cancer Treatment ◽  
The Impact

Inherent and acquired drug resistance is a cause of chemotherapy failure, and pharmacogenomic studies have begun to define gene variations responsible for varied drug metabolism, which influences drug efficacy. Platinum-based compounds are the most commonly used chemotherapeutic agents in the treatment of advanced stage lung cancer patients, and the glutathione metabolic pathway is directly involved in the detoxification or inactivation of platinum drugs. Consequently, genotypes corresponding to higher drug inactivation enzyme activity may predict poor treatment outcome. Available evidence is consistent with this hypothesis, although a definitive role for glutathione system genes in lung cancer prognosis needs to be elucidated. We present evidence supporting a role of the glutathione system in acquired and inherited drug resistance and/or adverse effects through the impact of either drug detoxification or drug inactivation, thus adversely effecting lung cancer treatment outcome. The potential application of glutathione system polymorphic genetic markers in identifying patients who may respond favorably, selecting effective antitumor drugs, and balancing drug efficacy and toxicity are discussed.

scholarly journals The role of comorbidity in the management and prognosis in nonsmall cell lung cancer: a population-based study

2017 ◽  
Vol 56 (7) ◽  
pp. 949-956 ◽  
Author(s):  
Jonas Nilsson ◽  
Anders Berglund ◽  
Stefan Bergström ◽  
Michael Bergqvist ◽  
Mats Lambe
Keyword(s):  
Lung Cancer ◽  
Cell Lung Cancer ◽  
Nonsmall Cell Lung Cancer ◽  
Population Based ◽  
Population Based Study
Sign in / Sign up

Export Citation Format

Share Document